U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07045571) titled 'MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer' on May 08.
Brief Summary: Developing a characteristic ctDNA methylation panel for pancreatic ductal adenocarcinoma and establishing an intelligent diagnostic and dynamic monitoring model based on ctDNA methylation.
Study Start Date: Oct. 30, 2022
Study Type: OBSERVATIONAL
Condition:
Pancreatic Neoplasm
Pancreas Cancer
Recruitment Status: RECRUITING
Sponsor: Yingbin Liu, MD, PhD, FACS
Information provided by (Responsible Party): Yingbin Liu, MD, PhD, FACS, Shanghai Jiao Tong University School of Medicine
Published by HT Digital Content Services ...